Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | KCNN3 | Q9UGI6 | 8/20 | 0.37 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.37 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20664459 | 0.80 | PDE10A (0.43) | PDE10APIM1PIM3PLK3PIM2 | |
| SCHEMBL16828091 | 0.80 | PDE10A (0.43) | PDE10APIM1PIM3PLK3PIM2 | |
| SCHEMBL4102510 | 0.80 | PDE10A (0.43) | PDE10AKCNN3PRKAA1KDRPRKAB2 | |
| SCHEMBL12364000 | 0.80 | PDE10A (0.43) | PDE10APIM1PIM3PLK3PIM2 | |
| SCHEMBL1934445 | 0.76 | PDE10A (0.40) | PDE10APIM1PIM3PLK3PIM2 | |
| SCHEMBL7431490 | 0.76 | PRKAB2 (0.54) | PDE10AKCNN3KCNN1KCNN2PRKAA1 | |
| SCHEMBL19953388 | 0.76 | LOXL2 (0.46) | PDE10APIM1PIM3PLK3PIM2 | |
| SCHEMBL4253867 | 0.76 | PIM1 (0.56) | PDE10APIM1PIM3PLK3PIM2 | |
| SCHEMBL30443263 | 0.73 | CCR1 (0.47) | PDE10AKCNN3KDRMAPK14CDK2 | |
| SCHEMBL12953626 | 0.73 | PIM1 (0.53) | PIM1PIM3PLK3PIM2KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110016036-B | Pyrazolo [1,5-a ] pyrimidine compound and preparation method and application thereof | 辽宁大学 | 2022-06-03 | — | — | CN | claimed |
| EP-3778604-B1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA FARBER CANCER INST INC (US) | 2026-01-07 | — | — | EP | disclosed |
| CN-117486885-A | Use of pyrazolopyrimidines | 中国科学院上海药物研究所 | 2024-02-02 | — | — | CN | disclosed |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| CN-110016036-B | Pyrazolo [1,5-a ] pyrimidine compound and preparation method and application thereof | 辽宁大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-110016036-B | Pyrazolo [1,5-a ] pyrimidine compound and preparation method and application thereof | 辽宁大学 | 2022-06-03 | — | — | CN | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | TEIJIN PHARMA LIMITED | 2006-06-22 | — | — | US | disclosed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | PDE10A 3189/4885PIM1 2880/4885PIM3 3769/4885 |
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | TYK2, JAK1, JAK2 | PDE10A 2917/4885PIM1 450/4885PIM3 610/4885 |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | PDE10A 4296/4885PIM1 460/4885PIM3 521/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | PDE10A 4705/4885PIM1 244/4885PIM3 273/4885 |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | PDE10A 1177/4885PIM1 453/4885PIM3 856/4885 |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | MAPKAPK2, MAPKAPK5, MAP4K2 | PDE10A 1284/4885PIM1 1208/4885PIM3 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.